Track Bioventus Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bioventus Inc. BVS · Stock Open Bioventus Inc. in new tab

13.31 USD
Add to portfolio
P/E
16.55
EPS
0.78
P/B
3.86
ROE
25.68
Beta
0.65
Target Price
17.60 USD
Bioventus Inc. logo

Bioventus Inc.

🧾 Earnings Recap – Q2 2026

Bioventus shares rose 4.2% post-earnings, driven by better-than-expected revenue growth and encouraging momentum across key growth segments, particularly Pain Treatments. The reaffirmation of full-year guidance and positive strategic developments underpinned investor optimism.

  • Q2 revenue increased 4%, led by strong double-digit growth in the Pain Treatments segment, notably the HA franchise and DUROLANE product.
  • Year-to-date HA business outperformed expectations, enabling reinvestment into growth areas like PRP, PNS, Ultrasonics, and International markets.
  • Leading indicators such as accelerating PRP capital placements, increased surgeon adoption of PNS, and growing Ultrasonics disposable usage signal strengthening market traction.
  • International segment showing accelerating momentum due to targeted market focus and new talent additions, with expectations for strong double-digit growth in H2 and full year.
  • Company reiterated full-year guidance and disclosed a strategic review including potential sale options, reflecting management’s commitment to maximizing shareholder value.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 3, 2026
P/E16.55
EPS0.78
Book Value3.35
Price to Book3.86
Debt/Equity95.08
% Insiders11.651%
Growth
Revenue Growth0.04%
Earnings Growth3.27%
Estimates
Forward P/E14.03
Forward EPS0.92
Target Mean Price17.60

DCF Valuation

Tweak assumptions to recompute fair value for Bioventus Inc. (BVS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Bioventus Inc. Logo Bioventus Inc. Analysis (BVS)

United States Health Care Official Website Stock

Is Bioventus Inc. a good investment? Bioventus Inc. (BVS) is currently trading at 13.31 USD. Market analysts have a consensus price target of 17.60 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 16.55. This valuation is generally in line with the broader market.

Earnings Schedule: Bioventus Inc. is expected to release its next earnings report on Nov. 3, 2026. The market consensus estimate for Forward EPS is 0.92.

Investor FAQ

Does Bioventus Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Bioventus Inc.?

Bioventus Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 3, 2026. The company currently has a trailing EPS of 0.78.

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Exchange Ticker
NMS (United States) BVS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion